ClinicalTrials.gg
RecruitingNCT06523374Endeavor-1Updated Feb 24, 2026

A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

An interventional study of Endoscopic brush cytology in Barrett's Esophagus and Esophageal Adenocarcinoma, sponsored by University Hospital, Antwerp. Recruiting at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University Hospital, Antwerp · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study serves, in part, to prepare for a future large cohort study. The goal of the study is:

  1. The collection of various tissue samples (blood, biopsies and "esophageal brushes") and their analysis.
  2. To set up standardized methods for different genetic analyses (DNA-FISH and so-called single cell sequencing) on the esophageal tissue samples.
  3. Evaluating the quality of life of Barrett's Esophagus patients and the degree of fear of getting cancer.

Patients with a Barrett's Esophagus can participate in the study if they are minimally 18 years old, are capable of giving informed consent (fully understanding what the study entails before giving consent to participate), have Barrett Esophagus and are referred to one of the participating centers due to suspicion of high-grade dysplasia or early esophageal cancer, for which the participant will be evaluated by endoscopic imaging and biopsy.

Study procedures:

  • An intake consultation will be planned, wherein the eligibility criteria will be assessed, and participant characteristics will be collected.
  • A routine gastroscopy will be planned twice during which several minimally-invasive interventions will be performed: drawing a blood sample, brush cytology during the endoscopy (a brush is used to obtain cells from the surface of the esophagus) and obtaining biopsy samples (small pieces of tissue). Each participant will need to undergo all the interventions.
  • Patients will have to complete questionnaires at three time points to assess their quality of life (EQ-5D-DL questionnaire) and fear of cancer recurrence (Cancer Worry Scale).
Read the detailed description

More specifically, you will have a standard endoscopy twice during which tissue samples will be taken from the esophagus to check for the severity of the disease. This is part of standard care. If you participate in the study, additional samples will be taken from the esophagus and also from the stomach (a total maximum of 10 samples of 1-2 mm). As a result, the endoscopic examination will take about 10-15 minutes longer than standard. Furthermore, in addition to the tissue samples, cells of the esophageal mucosa will be sampled (through 4 "esophageal brushes") and blood (4 tubes) will also be collected.

For this study, you will be contacted a total of three times. Once for a screening visit and twice for the sample collection described above. The screening and sample collection will take place during the already scheduled treatments and consultations. Afterwards, patient outcomes will be documented for the study until a maximum of 5 years after inclusion. This documentation will take place during the routine follow up so does not require any additional visits for the patients. Additionally you will be asked to complete two short questionnaires on your mobile phone at three time points during the study.

02

Conditions studied

  • Barrett's Esophagus
  • Esophageal Adenocarcinoma

Keywords

  • Barrett
  • Barrett's Esophagus
  • Endeavor
  • Esophageal cancer
  • Esophageal adenocarcinoma
03

In context

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

This study's planned enrollment of 50 is below the median of 62 across 187 interventional studies indexed under Barrett Esophagus.

Browse Barrett Esophagus studies →

Lead sponsor

University Hospital, Antwerp is the lead sponsor of 243 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of early esophageal Barrett cancer
  • Capable of receiving and of giving permission
  • Age 18 and upward

Exclusion criteria

Exclusion Criteria:

  • Patients with current known of the gastrointestinal tract other than the esophageal lesion
  • Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)
  • Esophageal varices
  • Uncontrollable coagulation disorders
  • Undergoing chemotherapy or immunotherapy or received chemotherapy \< 6 weeks prior to endoscopy
  • Undergoing radiotherapy within the esophageal region or received chemotherapy \< 6 months prior to endoscopy
  • WHO score > 3
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Endoscopic brush cytology

    Each participant will receive all interventions. A routine endoscopy will be planned during which several minimally invasive interventions will be performed: drawing a blood sample (standard of care), brush cytology (not standard of care) and biopsies (standard of care) during the endoscopy.

    Procedure: Endoscopic brush cytology

Interventions

  • ProcedureEndoscopic brush cytology

    A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.

06

What researchers measure

Primary outcomes

  1. Success rate of brush, biopsy and blood samples obtained from different sites for analysis by HTP technologies

    We will determine the success rate of obtaining material from different sites for analysis by high throughput technologies (Next Generation Sequencing) of the brush, biopsy or blood samples. A rate of analysable cells of at least 80% of the specimens will be regarded as successful.

    Time frame: 6-12 months

  2. Success rate of DNA-FISH analyses on the brush cytology samples

    Our second primary outcome measure for this pilot study is successful DNA-FISH analysis (successful = at least 50 cells that can be analyzed in at least 80% of participants) on the brush cytology samples for defining the final risk model that will be applied in the randomized controlled trial following the pilot study.

    Time frame: 6-12 months

Secondary outcomes

  1. Accuracy of a DNA-FISH based risk model

    The first secondary outcome is the accuracy of a DNA-FISH based risk model to distinguish low risk from high-risk early Barrett cancers. This will be assessed by endoscopic imaging and histo-pathological outcomes.

    Time frame: 6-24 months

  2. Correlation of a DNA-FISH based risk model

    The correlation of a DNA-FISH based risk model to distinguish low risk from high-risk early Barrett cancers with results obtained from Next Generation Sequencing.

    Time frame: 6-24 months

  3. Standard operating procedures for specimen collection

    A standard operating procedure describing the best method for obtaining brush cytology specimens and for obtaining the right tissue specimens via endoscopy will be created. The best method will be determined by the quality and number of analysable cells.

    Time frame: 6-24 months

  4. Standard operating procedures for logistical procedures

    A standard operating procedure (SOP) for the logistics for shipment, redistribution and storage of patient material and data of the different participating sites will be created based on the course of this pilot study. Interim logistical problems will be spontaneously reported by all sites and resolved with the central team. The final solutions ("best method") will be described in the SOP.

    Time frame: 6-24 months

  5. Successful participation and answering of questionnaires

    The participation and answering of the quality of life questionnaires and anxiety level questionnaires of at least 70% of the patients will be seen as successful.

    Time frame: 6-24 months

07

Study locations

9 of 9 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2026, 8 months after the start.

Of 65 non-industry interventional studies with no phase under Barrett Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 108. This study's planned 8 months is below that.

Counting every sponsor, half of 76 studies reached it within 45 months; a quarter within 23 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jul 26, 2024
StartActual
Aug 13, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Dec 2027
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06523374
Collaborators
Karolinska Institutet, Universal Diagnostics, Amsterdam UMC, Radboud University Medical Center, AZ Delta, University of Leipzig, IRCCS Ospedale San Raffaele, Karolinska University Hospital, University of Dublin, Trinity College, Heinrich-Heine University, Duesseldorf, GZA Ziekenhuizen Campus Sint-Augustinus, University Hospital, Ghent, Rigshospitalet, Denmark, Universitätsklinikum Leipzig, St. James's Hospital, Ireland, University Hospital, Lille
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Aug 13, 2025
Primary completion
Apr 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 24, 2026

Study contacts

Toon Mertens
Contact
Toon.mertens@uza.be
+3234368281
Luka Van der Veken
Contact
luka.vanderveken@uza.be
+3234368249
Sheila Krishnadath
principal investigator · Universitair Ziekenhuis Antwerpen (UZA)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion